TNFRSF10C (TNF receptor superfamily member 10c)

2003-02-01  

Identity

HGNC
LOCATION
8p21.3
LOCUSID
ALIAS
CD263,DCR1,DCR1-TNFR,LIT,TRAIL-R3,TRAILR3,TRID
FUSION GENES

Other Information

Locus ID:

NCBI: 8794
MIM: 603613
HGNC: 11906
Ensembl: ENSG00000173535

Variants:

dbSNP: 8794
ClinVar: 8794
TCGA: ENSG00000173535
COSMIC: TNFRSF10C

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000173535ENST00000356864O14798
ENSG00000173535ENST00000517558E5RJI1

Expression (GTEx)

0
50
100
150
200

Pathways

PathwaySourceExternal ID
Cytokine-cytokine receptor interactionKEGGko04060
ApoptosisKEGGko04210
Natural killer cell mediated cytotoxicityKEGGko04650
Cytokine-cytokine receptor interactionKEGGhsa04060
ApoptosisKEGGhsa04210
Natural killer cell mediated cytotoxicityKEGGhsa04650
MeaslesKEGGko05162
MeaslesKEGGhsa05162
Influenza AKEGGko05164
Influenza AKEGGhsa05164
Gene ExpressionREACTOMER-HSA-74160
Generic Transcription PathwayREACTOMER-HSA-212436
Transcriptional Regulation by TP53REACTOMER-HSA-3700989
TP53 Regulates Transcription of Cell Death GenesREACTOMER-HSA-5633008
TP53 Regulates Transcription of Death Receptors and LigandsREACTOMER-HSA-6803211

Protein levels (Protein atlas)

Not detected
Low
Medium
High

References

Pubmed IDYearTitleCitations
352260682023Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL.1
352260682023Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL.1
321114002020TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer.3
321114002020TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer.3
284203512017Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer.9
284203512017Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer.9
260506212016Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity.32
265427572016Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer.11
260506212016Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity.32
265427572016Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer.11
258088682015Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide.10
258088682015Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide.10
245348202014Does DcR1 (TNF-related apoptosis-inducing-ligand Receptor 3) have any role in human AMD pathogenesis?10
246498042014Membrane expression of trail receptors DcR1 and DcR2 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer.0
245348202014Does DcR1 (TNF-related apoptosis-inducing-ligand Receptor 3) have any role in human AMD pathogenesis?10

Citation

Dessen P

TNFRSF10C (TNF receptor superfamily member 10c)

Atlas Genet Cytogenet Oncol Haematol. 2003-02-01

Online version: http://atlasgeneticsoncology.org/gene/42607/tnfrsf10c